| Literature DB >> 20019899 |
Mark P Purdue1, Lawrence S Engel, Hilde Langseth, Larry L Needham, Aage Andersen, Dana B Barr, Aaron Blair, Nathaniel Rothman, Katherine A McGlynn.
Abstract
BACKGROUND: Recent findings suggest that exposure to organochlorine (OC) compounds, chlordanes and p,p'-dichlorodiphenyldichloroethylene (p,p'-DDE) in particular, may increase the risk of developing testicular germ cell tumors (TGCTs).Entities:
Keywords: chlordanes; organochlorine compounds; p,p′-dichloro-diphenyldichloroethylene; polychlorinated biphenyls; testicular germ cell tumors
Mesh:
Substances:
Year: 2009 PMID: 20019899 PMCID: PMC2790503 DOI: 10.1289/ehp.0800359
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Serum concentration of selected organochlorine insecticide compounds and risk of TGCTs.
| Lipid-adjusted analyte concentration (ng/g lipid) | ORs for concentration tertiles (reference group: tertile 1) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cases ( | Controls ( | Tertile 1 | Tertile 2 | Tertile 3 | ||||
| Analyte | Median (range) | Median (range) | OR (95% CI) | OR (95% CI) | ||||
| DDT metabolite | ||||||||
| | 20.7 (6.0–220.5) | 16.6 (0.3–171.9) | 0.36 | 17/16 | 17/11 | 0.8 (0.2–2.6) | 17/21 | 1.4 (0.4–4.5) |
| | 226.0 (92.2–584.1) | 194.6 (29.3–661.0) | 0.23 | 17/11 | 17/20 | 2.3 (0.7–7.2) | 17/18 | 2.1 (0.6–7.2) |
| | 2098.5 (750.0–9512.2) | 1833.2 (224.9–7436.3) | 0.07 | 17/11 | 17/18 | 1.8 (0.6–5.5) | 17/20 | 2.2 (0.7–6.5) |
| Chlordane | ||||||||
| Heptachlor epoxide | 12.0 (0.1–43.6) | 11.9 (0.2–27.4) | 0.18 | 16/12 | 16/16 | 1.7 (0.5–5.8) | 16/20 | 2.4 (0.6–9.1) |
| Oxychlordane | 13.4 (0.6–77.4) | 11.8 (0.8–79.4) | 0.05 | 16/11 | 15/20 | 3.0 (0.8–11.1) | 15/18 | 3.2 (0.6–16.8) |
| | 23.2 (10.7–76.9) | 20.5 (8.3–99.2) | 0.07 | 17/10 | 17/21 | 3.1 (0.8–11.6) | 17/18 | 2.6 (0.7–8.9) |
| Total | 47.3 (17.9–143.2) | 45.2 (19.0–206.0) | 0.048 | 17/13 | 17/17 | 1.8 (0.5–6.5) | 17/19 | 2.3 (0.6–7.2) |
| Other insecticide | ||||||||
| β-HCH | 143.0 (58.4–414.0) | 129.7 (59.7–295.9) | 0.20 | 17/15 | 17/13 | 1.0 (0.4–2.7) | 17/21 | 1.8 (0.5–6.1) |
| Dieldrin | 54.2 (0.6–177.9) | 54.7 (0.7–251.0) | 0.46 | 17/11 | 17/22 | 3.3 (0.8–12.7) | 17/15 | 2.1 (0.5–9.5) |
| γ-HCH | 6.4 (0.1–42.4) | 6.8 (0.2–45.1) | 0.89 | 17/17 | 17/15 | 1.0 (0.3–3.1) | 17/17 | 1.1 (0.2–5.0) |
| HCB | 713.4 (199.5–2458.2) | 568.6 (168.6–3185.9) | 0.26 | 17/15 | 17/13 | 1.1 (0.3–3.7) | 17/21 | 2.9 (0.5–15.2) |
| Mirex | 1.7 (0.1–26.0) | 1.5 (0.1–14.9) | 0.10 | 17/16 | 16/13 | 0.9 (0.3–2.9) | 16/17 | 1.2 (0.4–3.0) |
Abbreviations: nCa, number of cases; nCo, number of controls.
p-Value from Wilcoxon signed-rank test of matched case–control sets.
ORs and 95% CIs calculated from conditional logistic regression of matched case–control sets.
Serum concentration of selected PCB congeners and PCB groupings and risk of TGCTs.
| Lipid-adjusted analyte concentration (ng/g lipid) | ORs for concentration tertiles (reference group: tertile 1) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cases ( | Controls ( | Tertile 1 | Tertile 2 | Tertile 3 | ||||
| Analyte | Median (range) | Median (Range) | OR (95% CI) | OR (95% CI) | ||||
| Selected PCB congener | ||||||||
| 44 | 16.4 (0.5–92.4) | 16.9 (0.6–108.3) | 0.14 | 17/18 | 16/12 | 0.4 (0.1–2.5) | 17/18 | 0.6 (0.1–3.8) |
| 49 | 9.8 (0.4–81.7) | 10.9 (0.2–79.2) | 0.41 | 17/16 | 17/13 | 0.7 (0.1–3.4) | 17/20 | 1.2 (0.2–7.6) |
| 52 | 24.4 (3.7–103.4) | 23.2 (5.3–116.9) | 0.49 | 17/18 | 17/10 | 0.6 (0.2–1.9) | 17/20 | 1.0 (0.3–3.5) |
| 99 | 68.5 (35.0–408.4) | 62.6 (24.2–183.4) | 0.04 | 17/9 | 17/19 | 2.2 (0.7–7.3) | 17/21 | 2.2 (0.8–5.9) |
| 138 | 199.6 (87.2–891.7) | 177.3 (79.9–394.5) | 0.06 | 17/15 | 17/10 | 0.7 (0.3–2.0) | 17/24 | 1.8 (0.6–5.1) |
| 153 | 431.5 (166.0–1922.5) | 399.3 (187.1–860.7) | 0.10 | 17/16 | 17/14 | 0.9 (0.3–2.5) | 17/19 | 1.2 (0.4–3.4) |
| 167 | 11.2 (0.6–45.0) | 9.1 (0.1–24.3) | 0.02 | 16/10 | 16/13 | 2.2 (0.5–9.2) | 16/19 | 4.4 (1.0–19.8) |
| 183 | 30.4 (13.2–151.5) | 27.6 (11.1–59.0) | 0.07 | 17/14 | 16/15 | 1.0 (0.4–2.6) | 16/18 | 1.3 (0.5–3.5) |
| 195 | 7.9 (0.2–43.4) | 6.9 (0.3–17.6) | 0.19 | 16/10 | 16/20 | 1.9 (0.7–5.0) | 15/15 | 1.7 (0.6–4.6) |
| Total PCBs | 1845.4 (1014.8–8542.7) | 1751.1 (800.5–3470.0) | 0.17 | 17/14 | 17/16 | 1.1 (0.5–2.7) | 17/19 | 1.3 (0.5–3.8) |
| Degree of chlorination | ||||||||
| Low | 308.1 (56.9–1753.9) | 291.2 (70.4–1335.5) | 0.89 | 17/13 | 17/17 | 1.7 (0.5–6.5) | 17/19 | 2.2 (0.4–10.9) |
| Moderate | 1348.7 (596.8–6955.4) | 1295.2 (557.8–2866.2) | 0.10 | 17/13 | 17/16 | 1.2 (0.5–2.8) | 17/20 | 1.5 (0.6–4.1) |
| High | 87.5 (35.6–722.2) | 83.7 (31.6–202.1) | 0.42 | 17/15 | 17/11 | 0.7 (0.3–1.8) | 17/23 | 1.4 (0.6–3.3) |
| Mixed-function oxidase induction | ||||||||
| Phenobarbital type | 918.2 (412.2–4786.9) | 880.5 (404.0–1876.6) | 0.16 | 17/12 | 17/18 | 1.3 (0.6–3.0) | 17/19 | 1.5 (0.5–4.1) |
| Mixed type | 451.0 (218.6–2112.1) | 426.7 (170.7–919.1) | 0.07 | 17/13 | 17/14 | 1.1 (0.4–2.7) | 17/22 | 1.7 (0.6–4.8) |
| Wolff group | ||||||||
| 1 | 172.9 (113.3–846.1) | 166.2 (70.6–450.5) | 0.22 | 17/13 | 17/18 | 1.4 (0.5–3.9) | 17/18 | 1.4 (0.5–3.9) |
| 1A | 51.0 (6.7–275.8) | 53.6 (8.8–304.4) | 0.32 | 17/18 | 17/10 | 0.4 (0.1–1.7) | 17/21 | 1.0 (0.2–4.4) |
| 1B | 118.9 (49.8–742.3) | 109.4 (42.0–332.9) | 0.15 | 17/10 | 17/19 | 1.8 (0.7–5.0) | 17/20 | 1.8 (0.7–4.8) |
| 2 | 531.2 (278.0–2458.0) | 493.9 (210.4–1021.6) | 0.10 | 17/13 | 17/13 | 1.0 (0.4–2.3) | 17/23 | 1.6 (0.6–4.1) |
| 2A | 229.7 (115.8–1037.9) | 203.8 (89.3–603.7) | 0.16 | 17/13 | 17/14 | 1.4 (0.4–4.3) | 17/22 | 1.9 (0.6–5.6) |
| 2B | 297.3 (130.3–1420.1) | 275.8 (121.1–581.6) | 0.10 | 17/15 | 17/13 | 0.9 (0.4–2.2) | 17/21 | 1.4 (0.5–3.7) |
| 3 | 784.2 (312.5–3985.0) | 738.8 (333.9–1599.8) | 0.13 | 17/13 | 17/18 | 1.3 (0.5–3.1) | 17/18 | 1.3 (0.5–3.8) |
Abbreviations: nCa, number of cases; nCo, number of controls.
p-Value from Wilcoxon signed-rank test of matched case–control sets.
ORs and 95% CIs calculated from conditional logistic regression of matched case–control sets.
Congeners significantly associated with TGCTs or seminoma (Table 3) reported. Results for all congeners are provided in Supplemental Material, Table 2 (doi:10.1289/ehp.0800359.S1).
Sum of all 31 congeners included in the analysis.
Low: PCBs 11, 18, 28, 44, 49, 52, 66, and 74; moderate: PCBs 99, 105, 110, 118, 128, 138, 146, 153, 156, 157, 167, 170, 172, 177, 178, 180, 183, 187, and 189; high: PCBs 194, 195, 196, 201, 206, and 209.
Phenobarbital-type induction: PCBs 11, 52, 66, 99, 146, 153, 180, 183, 194, 195, 196, 206, and 209; mixed-type induction: PCBs 105, 118, 128, 138, 156, 157, 167, 170, and 189.
Wolff 1A: PCBs 44, 49, and 52; Wolff 1B: PCBs 177, 187, and 201; Wolff 2A: PCBs 66, 74, 105, 118, 156, and 167; Wolff 2B: PCBs 128, 138, and 170; Wolff 3: PCBs 99, 153, 180, 183, and 196.
Serum concentration of selected organochlorine compounds and risk of seminoma tumors.
| Median lipid-adjusted analyte concentration (ng/g lipid) | ORs for concentration tertiles (reference group: tertile 1) | |||||||
|---|---|---|---|---|---|---|---|---|
| Tertile 1 | Tertile 2 | Tertile 3 | ||||||
| Analyte | Seminoma ( | Controls ( | OR (95% CI) | OR (95% CI) | ||||
| Selected organochlorine insecticide | ||||||||
| | 2100.4 | 1768.2 | 0.06 | 12/10 | 13/10 | 1.0 (0.3–3.8) | 9/14 | 2.2 (0.5–8.7) |
| Oxychlordane | 14.3 | 11.8 | 0.006 | 10/6 | 13/15 | 3.2 (0.6–15.7) | 9/13 | 5.1 (0.7–36.8) |
| | 22.6 | 19.6 | 0.21 | 13/9 | 10/15 | 3.7 (0.7–19.0) | 11/10 | 1.6 (0.4–6.0) |
| Total chlordanes | 45.4 | 45.2 | 0.13 | 11/9 | 12/12 | 1.4 (0.3–5.5) | 10/12 | 1.6 (0.4–6.6) |
| PCB | ||||||||
| Total PCBs | 1819.7 | 1856.6 | 0.12 | 10/9 | 11/11 | 1.1 (0.4–3.3) | 13/14 | 1.2 (0.4–4.1) |
| Selected PCB congener | ||||||||
| 44 | 15.0 | 17.0 | 0.003 | 9/13 | 9/9 | 0.3 (0.03–3.0) | 15/12 | 0.2 (0.01–2.0) |
| 49 | 9.5 | 11.6 | 0.03 | 10/12 | 10/8 | 0.3 (0.02–3.0) | 14/14 | 0.3 (0.02–4.7) |
| 52 | 23.1 | 26.8 | 0.03 | 10/14 | 10/6 | 0.3 (0.05–1.6) | 14/14 | 0.4 (0.07–2.3) |
| 99 | 75.4 | 63.5 | 0.01 | 12/5 | 10/12 | 5.6 (0.9–36.3) | 12/17 | 4.4 (1.0–20.5) |
| 138 | 203.3 | 177.2 | 0.02 | 11/9 | 12/8 | 0.9 (0.3–3.0) | 11/17 | 2.1 (0.6–7.2) |
| 153 | 439.3 | 395.9 | 0.04 | 12/10 | 9/11 | 1.4 (0.4–4.7) | 13/13 | 1.2 (0.4–4.3) |
| 167 | 11.9 | 8.9 | 0.008 | 11/6 | 12/8 | 2.3 (0.4–13.4) | 10/15 | 6.7 (1.1–42.9) |
| 183 | 31.9 | 27.4 | 0.01 | 10/8 | 14/11 | 1.0 (0.3–3.5) | 8/14 | 2.9 (0.6–13.7) |
| 195 | 8.3 | 7.1 | 0.04 | 9/6 | 13/13 | 2.0 (0.5–7.2) | 8/13 | 3.0 (0.8–11.7) |
| Degree of chlorination | ||||||||
| Low | 309.9 | 291.6 | 0.46 | 11/10 | 8/11 | 2.3 (0.4–14.1) | 15/13 | 0.5 (0.04–5.4) |
| Moderate | 1421.8 | 1289.6 | 0.04 | 10/8 | 12/11 | 1.2 (0.4–3.4) | 12/14 | 1.5 (0.4–5.4) |
| High | 98.5 | 85.0 | 0.28 | 11/11 | 13/6 | 0.4 (0.1–1.5) | 10/17 | 1.9 (0.6–5.9) |
| Mixed-function oxidase induction | ||||||||
| Phenobarbital type | 935.1 | 882.0 | 0.10 | 11/8 | 11/12 | 1.4 (0.5–3.8) | 12/14 | 1.6 (0.5–5.8) |
| Mixed type | 465.4 | 424.4 | 0.03 | 11/8 | 11/10 | 1.3 (0.4–3.9) | 12/16 | 2.0 (0.6–6.9) |
| Wolff group | ||||||||
| 1 | 172.2 | 178.8 | 0.53 | 10/11 | 11/11 | 0.9 (0.2–3.3) | 13/12 | 0.8 (0.2–3.1) |
| 1A | 49.3 | 54.0 | 0.004 | 10/14 | 9/7 | 0.3 (0.1–1.8) | 15/13 | 0.3 (0.04–1.9) |
| 1B | 128.4 | 111.8 | 0.08 | 11/8 | 11/9 | 1.0 (0.3–3.3) | 12/17 | 1.9 (0.6–6.0) |
| 2 | 551.3 | 497.3 | 0.05 | 11/8 | 11/8 | 1.0 (0.3–3.5) | 12/18 | 1.9 (0.6–5.9) |
| 2A | 243.4 | 207.0 | 0.12 | 12/10 | 10/7 | 1.0 (0.2–3.9) | 12/17 | 1.6 (0.5–5.4) |
| 2B | 303.7 | 273.6 | 0.04 | 11/8 | 12/10 | 1.1 (0.4–3.2) | 11/16 | 2.4 (0.6–8.8) |
| 3 | 791.8 | 719.0 | 0.07 | 12/8 | 11/13 | 1.6 (0.5–4.7) | 11/13 | 1.8 (0.5–6.6) |
Abbreviations: nCa, number of cases; nCo, number of controls.
Category cut points are the same as those used in Tables 1 and 2.
p-Value from Wilcoxon signed-rank test of matched case–control sets.
ORs and 95% CIs calculated from conditional logistic regression of matched case–control sets.
Sum of all 31 congeners included in the analysis.
Results for all analytes are provided in Supplemental Material, Table 3 (doi:10.1289/ehp.0800359.S1).
Low: PCBs 11, 18, 28, 44, 49, 52, 66, and 74; moderate: PCBs 99, 105, 110, 118, 128, 138, 146, 153, 156, 157, 167, 170, 172, 177, 178, 180, 183, 187, and 189; high: PCBs 194, 195, 196, 201, 206, and 209.
Phenobarbital-type induction: PCBs 11, 52, 66, 99, 146, 153, 180, 183, 194, 195, 196, 206, and 209; mixed-type induction: PCBs 105, 118, 128, 138, 156, 157, 167, 170, and 189.
Wolff 1A: PCBs 44, 49, and 52; Wolff 1B: PCBs 177, 187, and 201; Wolff 2A: PCBs 66, 74, 105, 118, 156, and 167; Wolff 2B: PCBs 128, 138, and 170; Wolff 3: PCBs 99, 153, 180, 183, and 196 (Wolff et al. 1997).